Abstract
The widespread use of biologics has paved way for newer options in therapeutics for once incurable illnesses. Their large and complex protein structure, post-translational modifications, elaborate manufacturing/production process and risk for immunogenicity adds to the uniqueness of a biologic product. Patent expiration of innovator biologics has led to the development of biosimilars; biologics similar/comparable to the reference product in terms of quality, safety and efficacy. We discuss the clinical safety and regulatory requirements for biosimilars in various countries across the world. Future holds promise for biosimilars to provide affordable, efficacious and safe treatment to a vast majority of patients with significant cost savings to the nation.
Keywords: Biologic, biosimilar, immunogenicity, patent, regulation, safety.
Current Clinical Pharmacology
Title:Biosimilars: Current Scientific and Regulatory Considerations
Volume: 9 Issue: 1
Author(s): Preeta Kaur Chugh and Vandana Roy
Affiliation:
Keywords: Biologic, biosimilar, immunogenicity, patent, regulation, safety.
Abstract: The widespread use of biologics has paved way for newer options in therapeutics for once incurable illnesses. Their large and complex protein structure, post-translational modifications, elaborate manufacturing/production process and risk for immunogenicity adds to the uniqueness of a biologic product. Patent expiration of innovator biologics has led to the development of biosimilars; biologics similar/comparable to the reference product in terms of quality, safety and efficacy. We discuss the clinical safety and regulatory requirements for biosimilars in various countries across the world. Future holds promise for biosimilars to provide affordable, efficacious and safe treatment to a vast majority of patients with significant cost savings to the nation.
Export Options
About this article
Cite this article as:
Chugh Kaur Preeta and Roy Vandana, Biosimilars: Current Scientific and Regulatory Considerations, Current Clinical Pharmacology 2014; 9 (1) . https://dx.doi.org/10.2174/15748847113089990066
DOI https://dx.doi.org/10.2174/15748847113089990066 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Genetic and Environmental Factors in Complex Neurodevelopmental Disorders
Current Genomics Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Islet Amyloid Polypeptide and Diabetes
Current Protein & Peptide Science Structure, Function and Modulation of Chemokine Receptors: Members of the G-Protein-Coupled Receptor Superfamily
Mini-Reviews in Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Molecular Genetics and Epidemiology of Osteoporosis
Current Pharmacogenomics Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry